中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.017 seconds)

    Extract of Fraxinus excelsior seeds and therapeutic applications therefor
    2.
    发明授权
    Extract of Fraxinus excelsior seeds and therapeutic applications therefor 有权
    Fraxinus提取物优良种子及其治疗应用

    公开(公告)号：US08293292B2

    公开(公告)日：2012-10-23

    申请号：US13294058

    申请日：2011-11-10

    Applicant: Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques DiKansky ,  Alvin Ibarra

    Inventor： Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques DiKansky ,  Alvin Ibarra

    IPC: A61K36/63

    CPC classification number: A61K36/63 ,  A61K31/7088

    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.

    Abstract translation: 可以通过阻断脂肪合成，激活PPAR-α，增加降血糖活性，降低体重，控制空腹血浆胰岛素水平与高胰岛素血症的关系，以及促进胰岛素敏感性以及促进胰岛素敏感性的方法，将可以用于治疗受试者（包括人）的Fraxinus excelsior种子提取物 引起有益的急性促胰岛素作用。 Fraxinus excelsior种子提取物尤其包括分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2 - [（6-O- [b] -D-吡喃葡萄糖基 - D-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）甲酯，通常称为excelside A，分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基 - 2 - [（6-O-和bgr-D-吡喃葡萄糖基-β-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）2-（4-羟基苯基）乙酯，通常称为excelside B ，和化合物GI5，GI3，硝酸ide酯和油甙二甲酯。

    Extract of Lepidium meyenii roots for pharmaceutical applications
    6.
    发明授权
    Extract of Lepidium meyenii roots for pharmaceutical applications 有权
    用于制药应用的梅毒根提取物

    公开(公告)号：US06267995B1

    公开(公告)日：2001-07-31

    申请号：US09261806

    申请日：1999-03-03

    Applicant: Bo Lin Zheng ,  Calvin Hyungchan Kim ,  Stephen Wolthoff ,  Kan He ,  Lingling Rogers ,  Yu Shao ,  Qun Yi Zheng

    Inventor： Bo Lin Zheng ,  Calvin Hyungchan Kim ,  Stephen Wolthoff ,  Kan He ,  Lingling Rogers ,  Yu Shao ,  Qun Yi Zheng

    IPC: A61K3578

    CPC classification number: A61K36/31

    Abstract: An isolated composition obtained by extracting Lepidium meyenii roots is provided. The composition is substantially free of cellulose and comprises between about 5% and about 9% of benzyl isothiocyanate, between about 1% and about 3% of Lepidium sterol component, between about 20% and about 30% of Lepidium fatty acid component, and about 10% or more of macamide component. The composition is prepared by a process which comprises contacting Lepidium meyenii roots with a first aqueous solvent of about 90% vol-% or more water, then separating the residual Lepidium meyenii root material from the first contacted aqueous solvent, then contacting the residual Lepidium meyenii root material with a second aqueous solvent which comprises a mixture of an alcohol and water having about 90 vol-% alcohol or more to form a liquor, and then finally concentrating the liquor to obtain the composition. The composition can be used for treating cancer and sexual dysfunction.

    Abstract translation: 提供了通过提取梅毒根获得的分离组合物。 所述组合物基本上不含纤维素，并且包含约5％至约9％的异硫氰酸苄酯，约1％至约3％的Lepidium sterol组分，约20％至约30％的Lepidium脂肪酸组分和约 10％以上的macamide成分。 组合物通过以下方法制备，该方法包括使梅毒根与约90％体积％或更多的水的第一含水溶剂接触，然后从残留的第一次接触的水性溶剂中分离剩余的梅毒根部物质，然后将剩余的梅毒 根部材料与第二含水溶剂组成，其包含具有约90体积％醇或更多醇的醇和水的混合物以形成液体，然后最终将液体浓缩以获得组合物。 该组合物可用于治疗癌症和性功能障碍。

    Extract of Rosmarinus officinalis L. leaves for pharmaceutical applications
    8.
    发明授权
    Extract of Rosmarinus officinalis L. leaves for pharmaceutical applications 有权
    迷迭香提取物用于制药应用

    公开(公告)号：US09011936B2

    公开(公告)日：2015-04-21

    申请号：US12580783

    申请日：2009-10-16

    Applicant: Kan He ,  Marc Roller ,  Alvin Ibarra ,  Naisheng Bai ,  Jacques DiKansky

    Inventor： Kan He ,  Marc Roller ,  Alvin Ibarra ,  Naisheng Bai ,  Jacques DiKansky

    IPC: A61K36/53 ,  A61K36/00

    CPC classification number: A61K36/53

    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.

    Abstract translation: 公开了通过施用迷迭香提取物来减轻氧化应激，调节血糖水平和控制胰脂肪酶活性的方法。 这些方法可用于帮助体重和身体脂肪，预防肥胖，以及治疗高血糖症，高胰岛素血症，心血管疾病和2型糖尿病。 优选的提取物含有20％或50％的鼠尾草酸。

    Boundary delineation system
    9.
    发明授权
    Boundary delineation system 有权
    边界划界系统

    公开(公告)号：US08477151B2

    公开(公告)日：2013-07-02

    申请号：US12273202

    申请日：2008-11-18

    Applicant: Kan He

    Inventor： Kan He

    IPC: G09G5/00 ,  G06F17/00 ,  G06T11/20

    CPC classification number: G06T11/206

    Abstract: Methods and systems for boundary delineation are described. In one embodiment, a living unit identifier may be translated into a translated geographic location point. The living unit identifier may be within a distribution area. A closed plane living unit-based figure that bounds the translated geographic location point may be delineated. An additional closed plane living unit-based figure that bounds a geographic location point may be delineated. The geographic location point may be associated with an additional living unit identifier within the distribution area. The closed plane living unit-based figure and the additional closed plane living unit-based figure may be merged to create a distribution area figure of the distribution area. Additional methods and systems are disclosed.

    Abstract translation: 描述了边界描绘的方法和系统。 在一个实施例中，生物单元标识符可以被翻译成翻译的地理位置点。 生活单元标识符可以在分配区域内。 可以划定限制翻译的地理位置点的封闭平面生活单位数字。 可以划定限制地理位置点的附加的基于平面的生活单位数字。 地理位置点可以与分配区域内的附加生命单元标识符相关联。 可以合并封闭平面生活单位数字和附加闭路平面生活单位数字，形成分布区域的分布区域图。 公开了附加的方法和系统。

    Imidazole alkaloids from Lepidium meyenii and methods of usage
    10.
    发明授权
    Imidazole alkaloids from Lepidium meyenii and methods of usage 失效
    来自梅毒的咪唑生物碱及其使用方法

    公开(公告)号：US06878731B2

    公开(公告)日：2005-04-12

    申请号：US10219056

    申请日：2002-08-14

    Applicant: Baoliang Cui ,  Bo Lin Zheng ,  Kan He ,  Qun Yi Zheng

    Inventor： Baoliang Cui ,  Bo Lin Zheng ,  Kan He ,  Qun Yi Zheng

    IPC: C07D233/10 ,  C07D233/56 ,  A61K31/415

    CPC classification number: C07D233/58

    Abstract: The present invention relates to novel imidazole alkaloid compounds that have been isolated as a form of chloride salt from a root extract of Lepidium meyenii Walp, with the common name Maca, and identified below as 1,3-bis(phenylmethyl)-4,5-dimethyl-1H-imidazlium chloride and 1,3-bis(phenylmethyl)-2,4,5-trimethyl-1H-imidazlium chloride, compounds (1) and (2), respectively. The present invention further relates to the use of these novel compounds (1) and (2) to treat proliferative diseases, such as but not limited to cancer.

    Abstract translation: 本发明涉及以通用名称Maca从马铃薯Lepidium meyenii Walp的根提取物中分离为氯化物形式的新型咪唑生物碱化合物，下文称为1,3-双（苯基甲基）-4,5 - 二甲基-1H-咪唑氯化物和1,3-双（苯基甲基）-2,4,5-三甲基-1H-咪唑鎓氯化物，化合物（1）和（2）。本发明还涉及使用 这些新化合物（1）和（2）用于治疗增殖性疾病，例如但不限于癌症。

Patent Agency Ranking